Business Standard

India's first indigenous mRNA vax Gemcovac-19 likely to be available soon

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled

Gennova
Premium

Gennova Biopharmaceuticals

Sohini Das Mumbai
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, announced that its mRNA vaccine - Gemcovac-19 - against Covid-19 received the Emergency Use Authorization (EUA) from the office of the Drugs Controller General of India (DCGI).

Gemcovac-19 is the very first mRNA vaccine developed in India and only third mRNA vaccine to be approved for COVID-19 in the world.

Gennova Biopharmaceuticals Ltd aims to produce around 4 - 5 million doses per month and this capacity can be quickly doubled.

Apart from India, Gennova aims to provide access to low-and middle-income countries around the world to the vaccine to blunt

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in